不同基因型别纹带棒状杆菌耐药特点和生物膜形成能力分析

doi:10.3969/j.issn.1673-8640.2022.06.001

检验医学 ›› 2022, Vol. 37 ›› Issue (6): 505-509.DOI: 10.3969/j.issn.1673-8640.2022.06.001

• 临床应用研究·论著 • 下一篇

不同基因型别纹带棒状杆菌耐药特点和生物膜形成能力分析

孙伟¹, 夏帅², 樊玉健³, 马立艳¹()

1.首都医科大学附属北京友谊医院临床检验中心,北京 100050
2.首都医科大学附属北京友谊医院危急重症中心,北京 100050
3.首都医科大学临床检验诊断学系,北京 100069

收稿日期:2021-06-24 修回日期:2021-09-21 出版日期:2022-06-30 发布日期:2022-07-28
通讯作者: 马立艳
作者简介:马立艳,E-mail： happy_mayan@ccmu.edu.cn。
孙伟,女,1981年生,博士,副主任检验师,主要从事临床微生物检验和相关致病机制研究。
基金资助:
首都卫生发展科研专项(2018-1-4081)

Drug resistance and biofilm formation abilities of Corynebacterium striatum with different genotypes

SUN Wei¹, XIA Shuai², FAN Yujian³, MA Liyan¹()

1. Center of Clinical Laboratory,Beijing Friendship Hospital,Capital Medical University,Beijing 100050,China
2. Emergency and Critical Care Center,Beijing Friendship Hospital,Capital Medical University,Beijing 100050,China
3. Faculty of Clinical Laboratory Diagnosis,Capital Medical University,Beijing 100069,China

Received:2021-06-24 Revised:2021-09-21 Online:2022-06-30 Published:2022-07-28
Contact: MA Liyan

摘要/Abstract

摘要：

目的分析不同基因型别纹带棒状杆菌的药物敏感性和生物膜形成能力,为临床诊治纹带棒状杆菌相关感染提供实验室依据。方法收集2018年1月—2020年12月首都医科大学附属北京友谊医院临床分离的36株纹带棒状杆菌（21株分离自无菌体液样本、15株分离自清洁中段尿样本）,进行多位点序列分型（MLST）;采用琼脂稀释法检测36株纹带棒状杆菌对10种抗菌药物的敏感性,采用MTT法分析其生物膜形成能力。结果 36株纹带棒状杆菌主要分离自免疫功能低下的老年患者,有9个ST型别,其中ST6（36.1%）和ST2（25.0%）为优势基因型别。36株纹带棒状杆菌均为多重耐药菌（MDR）,仅对万古霉素和利奈唑胺100%敏感。ST2型菌株以四环素敏感株为主,ST6型菌株以庆大霉素和利福平敏感株为主。所有菌株均具有在聚苯乙烯表面形成生物膜的能力,其中ST2型菌株与其他型别菌株比较,普遍具有更强的生物膜形成能力（P<0.05）。结论不同基因型别的纹带棒状杆菌生物膜形成能力和药物敏感性存在差异,临床应合理选用抗菌药物,避免造成机会性感染和院内感染。

关键词: 纹带棒状杆菌, 药物敏感性, 多位点序列分型, 生物膜

Abstract:

Objective To study the characteristics of drug susceptibility and biofilm formation ability of Corynebacterium striatum with different genotypes,and to provide a reference for clinical diagnosis and therapy. Methods Totally,36 isolates of Corynebacterium striatum were collected from January 2018 to December 2021,which included 21 isolates from sterile body fluid specimens and the other 15 isolates from clean middle urine specimens. Multilocus sequence typing（MLST） genotyping,drug susceptibility test（agar dilution method） to 10 agents and biofilm formation determination（MTT） were carried out. Results Totally,36 isolates of Corynebacterium striatum were isolated mainly from immuno-suppressed elder patients,9 genotypes were classified with MLST method,and ST6（36.1%） and ST2（25.0%） were the most popular genotypes. All the 36 isolates were multi-drug resistance（MDR） bacteria,and they were sensitive to vancomycin and linezolid（100%）. Most ST2 isolates were sensitive to tetracycline,while most ST6 isolates were sensitive to gentamicin and rifampin. The biofilm formation determination showed that all the 36 isolates could form biofilm on the polystyrene surface,but the ST2 ones had stronger biofilm formation ability compared with the other genotypes（P<0.05）. Conclusions Different genotypes of Corynebacterium striatum have different biofilm formation abilities and drug susceptibilities to commonly used antibiotics. In the process of clinical diagnosis and treatment,clinicians should pay more attention to the rational use of antibiotics,which will help to avoid opportunistic infections and nosocomial infections.

Key words: Corynebacterium striatum, Drug susceptibility, Multilocus sequence typing, Biofilm

中图分类号:

R446.1

孙伟, 夏帅, 樊玉健, 马立艳. 不同基因型别纹带棒状杆菌耐药特点和生物膜形成能力分析[J]. 检验医学, 2022, 37(6): 505-509.

SUN Wei, XIA Shuai, FAN Yujian, MA Liyan. Drug resistance and biofilm formation abilities of Corynebacterium striatum with different genotypes[J]. Laboratory Medicine, 2022, 37(6): 505-509.

图/表 3

参考文献 21

[1]	GE Y, LU J, FENG S, et al. A case of catheter related bloodstream infection by Corynebacterium striatum[J]. IDCases, 2020, 22:e00987.
[2]	HOLLNAGEL K, WILLEN J, ELLIS M, et al. Chronic Corynebacterium striatum septic arthritis in a patient referred for total knee arthroplasty[J]. Case Rep Orthop, 2020, 2020:1392182.
[3]	GARCIA C M, MCKENNA J, FAN L, et al. Corynebacterium striatum bacteremia in end-stage renal disease:a case series and review of literature[J]. R I Med J(2013), 2020, 103(8):46-49.
[4]	ZHANG M J, CAO X J, FAN J, et al. Corynebacterium striatum meningitis combined with suspected brain and lung abscesses:a case report and review[J]. BMC Infect Dis, 2020, 20(1):389.
[5]	FERNÁNDEZ-ESGUEVA M, PÉREZ-JIMENO N, RODA-ROJO V, et al. Corynebacterium striatum prosthetic joint infection[J]. Enferm Infecc Microbiol Clin(Engl Ed), 2019, 37(7):480-481.
[6]	SHARIFF M, ADITI A, BERI K. Corynebacterium striatum:an emerging respiratory pathogen[J]. J Infect Dev Ctries, 2018, 12(7):581-586.
[7]	SUH J W, JU Y, LEE C K, et al. Molecular epidemiology and clinical significance of Corynebacterium striatum isolated from clinical specimens[J]. Infect Drug Resist, 2019, 12:161-171.
[8]	DATTA P, GUPTA V, GUPTA M, et al. Corynebacterium striatum,an emerging nosocomial pathogen:case reports[J]. Infect Disord Drug Targets, 2021, 21(2):301-303.
[9]	尚红, 王毓三, 申子瑜. 《全国临床检验操作规程(第4版)》[M]. 北京: 人民卫生出版社, 2015.
[10]	KANG S J, CHOI S M, CHOI J A, et al. Factors affecting the clinical relevance of Corynebacterium striatum isolated from blood cultures[J]. PLoS One, 2018, 13(6):e0199454.
[11]	Clinical and Laboratory Standards Institute. Methods for antimicrobial dilution and disk susceptibility testing of infrequently isolated or fastidious bacteria[S]. CLSI,M45, 2016.
[12]	SILVA-SANTANA G, SILVA C M F, OLIVELLA J G B, et al. Worldwide survey of Corynebacterium striatum increasingly associated with human invasive infections,nosocomial outbreak,and antimicrobial multidrug-resistance,1976-2020[J]. Arch Microbiol, 2021, 203(5):1863-1880.
[13]	SOUZA C, MOTA H F, FARIA Y V, et al. Resistance to antiseptics and disinfectants of planktonic and biofilm-associated forms of Corynebacterium striatum[J]. Microb Drug Resist, 2020, 26(12):1546-1558.
[14]	LEYTON B, RAMOS J N, BAIO P V P, et al. Treat me well or will resist:uptake of mobile genetic elements determine the resistome of Corynebacterium striatum[J]. Int J Mol Sci, 2021, 22(14):7499.
[15]	MCMULLEN A R, ANDERSON N, WALLACE M A, et al. When good bugs go bad:epidemiology and antimicrobial resistance profiles of Corynebacterium striatum,an emerging multidrug-resistant,opportunistic pathogen[J]. Antimicrob Agents Chemother, 2017, 61(11):e01111-e01117.
[16]	WANG X, ZHOU H, CHEN D, et al. Whole-genome sequencing reveals a prolonged and persistent intrahospital transmission of Corynebacterium striatum,an emerging multidrug-resistant pathogen[J]. J Clin Microbiol, 2019, 57(9):e00683-19.
[17]	SOUZA C, FARIA Y V, SANT'ANNA L O, et al. Biofilm production by multiresistant Corynebacterium striatum associated with nosocomial outbreak[J]. Mem Inst Oswaldo Cruz, 2015, 110(2):242-248.
[18]	RAMOS J N, SOUZA C, FARIA Y V, et al. Bloodstream and catheter-related infections due to different clones of multidrug-resistant and biofilm producer Corynebacterium striatum[J]. BMC Infect Dis, 2019, 19(1):672.
[19]	WANG J, WANG Y, Du X, et al. Rapid transmission of multidrug-resistant Corynebacterium striatum among susceptible patients in a tertiary hospital in China[J]. J Infect Dev Ctries, 2016, 10(12):1299-1305.
[20]	ALIBI S, RAMOS-VIVAS J, BEN SELMA W, et al. Virulence of clinically relevant multidrug resistant Corynebacterium striatum strains and their ability to adhere to human epithelial cells and inert surfaces[J]. Microb Pathog, 2021, 155:104887.
[21]	SOUZA C, SIMPSON-LOUREDO L, MOTA H F, et al. Virulence potential of Corynebacterium striatum towards Caenorhabditis elegans[J]. Antonie Van Leeuwenhoek, 2019, 112(9):1331-1340.

抗菌药物	ST2 （9株）		ST6 （13株）		其他7种型别（14株）
抗菌药物	MIC₅₀	MIC₉₀	MIC₅₀	MIC₉₀	MIC₅₀	MIC₉₀
万古霉素	0.5	0.5	0.5	0.5	0.5	0.5
利奈唑胺	0.5	0.5	0.5	0.5	0.5	0.5
四环素	4	4	32	64	32	64
庆大霉素	16	16	4	4	4	>32
利福平	>64	>64	1	1	1	>64
红霉素	2	8	>64	>64	2	>64
青霉素	>32	>32	>32	>32	>32	>32
环丙沙星	32	32	32	32	32	32
头孢噻肟	>64	>64	>64	>64	>64	>64
克林霉素	>64	>64	>64	>64	>64	>64

抗菌药物	ST2 （9株）		ST6 （13株）		其他7种型别（14株）
抗菌药物	MIC₅₀	MIC₉₀	MIC₅₀	MIC₉₀	MIC₅₀	MIC₉₀
万古霉素	0.5	0.5	0.5	0.5	0.5	0.5
利奈唑胺	0.5	0.5	0.5	0.5	0.5	0.5
四环素	4	4	32	64	32	64
庆大霉素	16	16	4	4	4	>32
利福平	>64	>64	1	1	1	>64
红霉素	2	8	>64	>64	2	>64
青霉素	>32	>32	>32	>32	>32	>32
环丙沙星	32	32	32	32	32	32
头孢噻肟	>64	>64	>64	>64	>64	>64
克林霉素	>64	>64	>64	>64	>64	>64

不同基因型别纹带棒状杆菌耐药特点和生物膜形成能力分析

Drug resistance and biofilm formation abilities of Corynebacterium striatum with different genotypes

RichHTML

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

图/表 3

参考文献 21

相关文章 15

编辑推荐

Metrics

[1]	王佳玮, 朱威南, 陈颖盈, 季萍, 王颖. 血培养分离碳青霉烯类耐药肺炎克雷伯菌临床分布和耐药基因分析[J]. 检验医学, 2023, 38(4): 362-367.
[2]	邓劲, 刘雅, 吴思颖, 廖全凤, 张为利, 肖玉玲, 谢轶, 马莹, 康梅. 抗菌药物体外联合药物敏感性试验方法[J]. 检验医学, 2023, 38(4): 385-393.
[3]	陈庆, 徐蓉, 孙景勇. 上海地区支气管扩张症患者铜绿假单胞菌耐药机制和分子流行病学特征[J]. 检验医学, 2023, 38(11): 1020-1025.
[4]	邓晨, 戴家泽, 邱丽红, 沈威廷, 蔡木发, 罗文英. 湛江地区高毒力肺炎克雷伯菌分子流行特征[J]. 检验医学, 2023, 38(11): 1026-1031.
[5]	茹浩浩, 陈连勇, 杨星, 陈涛, 闫双群, 许琳. Xpert MTB/RIF与结核分枝杆菌利福平耐药表型检测一致性分析[J]. 检验医学, 2023, 38(11): 1032-1035.
[6]	刘婧娴, 陈星月, 赵晶, 刘瑛. 非妊娠成人无乳链球菌感染临床特点及分子流行病学研究进展[J]. 检验医学, 2022, 37(8): 793-797.
[7]	温庆辉, 黎凤英, 李燕嫦, 黄金印, 王凤平. 不同浓度 EDTA 对产 ESBL多重耐药大肠埃希菌抗菌药物敏感性的恢复作用[J]. 检验医学, 2022, 37(3): 205-208.
[8]	宋皓月, 舒文. 肉芽肿性乳腺炎患者结核硬脂酸棒状杆菌毒力因子和耐药性分析[J]. 检验医学, 2022, 37(11): 1075-1078.
[9]	胡桂花, 胡先福. 胆道疾病患者胆汁样本病原菌分布和耐药特征[J]. 检验医学, 2022, 37(10): 952-954.
[10]	张亚茹, 凌丽燕, 陈敏. EUCAST和CLSI微量肉汤稀释法白念珠菌体外药物敏感性试验结果比较[J]. 检验医学, 2022, 37(10): 974-978.
[11]	张冠怡, 姚冬婷, 王健, 胡晓波. 光滑念珠菌耐药机制及中西药治疗光滑念珠菌感染研究进展[J]. 检验医学, 2021, 36(7): 761-765.
[12]	郁晨蕾, 江渊, 李静, 王莉莉, 陈炜, 沈旭晖, 张阳奕. 细菌超声分散计数仪在结核分枝杆菌最小抑菌浓度检测中的应用[J]. 检验医学, 2021, 36(6): 650-655.
[13]	王东江, 郭建. 免疫功能正常者新生隐球菌感染1例报道[J]. 检验医学, 2021, 36(5): 577-580.
[14]	陈蓉, 张敏敏, 夏启航, 钱诚凯, 崔琳, 刘学杰, 徐蓉, 王庆忠, 葛平, 黄维纲, 王敬华. 上海地区真菌培养鉴定及体外药物敏感性试验室间质量评价结果分析[J]. 检验医学, 2021, 36(4): 441-443.
[15]	乔玉莉, 黄宗帅, 田月如, 关明, 蒋晓飞. 血培养瓶增菌法快速鉴定和快速药物敏感性试验可行性分析[J]. 检验医学, 2021, 36(3): 270-274.